Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.39 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.39 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | AHR | P35869 | 1/20 | 0.32 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | HK1 | P19367 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8345058 | 0.88 | MAPT (0.43) | ALOX15HSD17B10NPC1MAPK13MAPK12 | |
| SCHEMBL429453 | 0.78 | ALOX15 (0.43) | ALOX15HSD17B10NPC1MAPK13MAPK12 | |
| SCHEMBL4166749 | 0.71 | TSHR (0.53) | HTR2CTSHRPLAU | |
| Indoline SCHEMBL5629 | 0.70 | — | — | |
| Indoline SCHEMBL29360339 | 0.70 | — | — | |
| Indoline SCHEMBL87372 | 0.70 | HTR2C (0.46) | ALOX15HSD17B10NPC1MAPK13MAPK12 | |
| SCHEMBL2203 | 0.70 | NPC1 (0.42) | ALOX15HSD17B10NPC1MAPK13MAPK12 | |
| Indoline SCHEMBL23295083 | 0.69 | HTR2C (0.50) | ALOX15HSD17B10NPC1MAPK13MAPK12 | |
| Indoline SCHEMBL11401846 | 0.69 | HTR2C (0.50) | ALOX15HSD17B10NPC1MAPK13MAPK12 | |
| Indoline SCHEMBL1587228 | 0.69 | HTR2C (0.50) | ALOX15HSD17B10NPC1MAPK13MAPK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2134342-B1 | MONOCYCLIC ANILIDE SPIROLACTAM CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2013-01-30 | — | — | EP | claimed |
| US-8148390-B2 | Monocyclic anilide spirolactam CGRP receptor antagonists | Merck, Sharp & Dohme, Corp. (US) | 2012-04-03 | — | — | US | claimed |
| US-20100152216-A1 | MONOCYCLIC ANILIDE SPIROLACTAM CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2010-06-17 | — | — | US | claimed |
| EP-2134342-A2 | MONOCYCLIC ANILIDE SPIROLACTAM CGRP RECEPTOR ANTAGONISTS | Merck & Co., Inc. (US) | 2009-12-23 | — | — | EP | claimed |
| WO-2009131246-A1 | SORDARIN DERIVATIVES FOR PREVENTING OR TREATING INFECTIOUS DISEASES CAUSED BY PATHOGENIC MICROORGANISMS | ASTELLAS PHARMA INC. (JP) | 2009-10-29 | — | — | WO | claimed |
| WO-2008112159-A2 | MONOCYCLIC ANILIDE SPIROLACTAM CGRP RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2008-09-18 | — | — | WO | claimed |
| EP-0552489-B1 | Peptide, production and use thereof | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1998-03-04 | — | — | EP | claimed |
| US-5614497-A | TREATMENT OF HYPERTENSION, CARDIOVASCULAR DISEASE AND RENAL DISEASE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-03-25 | — | — | US | claimed |
| EP-0552489-A2 | Peptide, production and use thereof | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-07-28 | — | — | EP | claimed |
| US-4638000-A | HYPOTENSIVES, ANGIOTENSIN INHIBITORS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1987-01-20 | — | — | US | claimed |
| US-4548932-A | ANGIOTENSIN INHIBITOR, HYPOTENSIVE AGENT | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1985-10-22 | — | — | US | claimed |
| EP-0063826-B1 | 2-AMINO-BENZOIC-ACID DERIVATIVES, THEIR PREPARATION AND THEIR USE AS MEDICINES OR INTERMEDIATES | Dr. Karl Thomae GmbH (DE) | 1984-12-05 | — | — | EP | claimed |
| CN-109311929-B | SECO macrolide compounds | 塞尔维塔公司 | 2022-10-04 | — | — | CN | disclosed |
| EP-3212637-B1 | DOPAMINE D3 RECEPTOR ANTAGONISTS COMPOUNDS | INDIVIOR UK LTD (GB) | 2021-06-02 | — | — | EP | disclosed |
| EP-3331886-B1 | DOPAMINE D3 RECEPTOR ANTAGONISTS HAVING A BICYCLO MOIETY | INDIVIOR UK LTD (GB) | 2020-07-15 | — | — | EP | disclosed |
| US-10654842-B2 | Dopamine D3 receptor antagonist compounds | INDIVIOR UK LIMITED (GB) | 2020-05-19 | — | — | US | disclosed |
| EP-0156455-A2 | Condensed seven-membered ring compounds, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1985-10-02 | — | — | EP | disclosed |
| EP-0135349-A1 | Condensed seven-membered ring compounds and their production and use | Takeda Chemical Industries, Ltd. (JP) | 1985-03-27 | — | — | EP | disclosed |
| EP-0063826-B1 | 2-AMINO-BENZOIC-ACID DERIVATIVES, THEIR PREPARATION AND THEIR USE AS MEDICINES OR INTERMEDIATES | Dr. Karl Thomae GmbH (DE) | 1984-12-05 | — | — | EP | disclosed |
| EP-0063826-A2 | 2-Amino-benzoic-acid derivatives, their preparation and their use as medicines or intermediates | Dr. Karl Thomae GmbH (DE) | 1982-11-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10654842-B2 | Dopamine D3 receptor antagonist compounds | DRD3, DRD2, DRD4 | ALOX15 3716/4885HSD17B10 2642/4885NPC1 3367/4885 |
| US-20100152216-A1 | MONOCYCLIC ANILIDE SPIROLACTAM CGRP RECEPTOR ANTAGONISTS | BDKRB1, BDKRB2, CALCRL | ALOX15 1894/4885HSD17B10 2661/4885NPC1 717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.